CEDRIC WILLIS: Open Payments
NPI 1801196589 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,488 in 124 payments from 20 companies in 2025. Trend: 2023 $3,194 · 2024 $3,030 · 2025 $2,488
Food & beverage: $2,400Education: $87
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $692 |
| Janssen Biotech, Inc. | 15 | $326 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $282 |
| Phathom Pharmaceuticals, Inc. | 9 | $186 |
| QOL Medical, LLC | 9 | $183 |
| GENZYME CORPORATION | 6 | $163 |
| Aimmune Therapeutics, Inc. | 5 | $124 |
| Lilly USA, LLC | 5 | $104 |
| Intercept Pharmaceuticals, Inc. | 4 | $82 |
| Ipsen Biopharmaceuticals, Inc | 3 | $66 |
Products named: TREMFYA, LINZESS, XIFAXAN, VOQUEZNA, Sucraid, SKYRIZI, DUPIXENT, CREON.
Industry payments across LA — which companies pay providers there.
